References
- Yao Q, Wang B, An X, et al. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect. 2018;7:220–231.
- Kaur H, Werstuck GH. The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data. CJC Open. 2021;3:1238–1248.
- Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019;42:1104–1111.
- Yassin A, Saad F, Alwani M, et al. The effects of long-term testosterone treatment on endocrine parameters in hypogonadal men: 12-year data from a prospective controlled registry study. Aging Male. 2022;25:185–191.
- Yassin A, AlRumaihi K, Alzubaidi R, et al. Testosterone, testosterone therapy and prostate cancer. Aging Male. 2019;22:219–227.
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–1181.
- Best J, Gonzalez D, Masterson T, et al. A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate. Can Urol Assoc J InternetAvailable from. 2020 [cited 2022 Nov 26];15(2). https://cuaj.ca/index.php/journal/article/view/6651
- Jockenhövel F, Bullmann C, Schubert M, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism. 1999;48:590–596.
- Conaglen HM, Paul RG, Yarndley T, et al. Retrospective investigation of testosterone undecanoate depot for the long‐term treatment of male hypogonadism in clinical practice. J Sex Med. 2014;11:574–582.
- Dean JD, Carnegie C, Rodzvilla J, et al. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2005;7:87–94.
- Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Ser A. 2003;58:M618–625.
- Ramasamy R, Masterson TA, Best JC, et al. Effect of natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single center, open label, single arm trial. J Urol. 2020;204:557–563.
- Yee A, Uloko M, Goldstein I. 011 clinical experience with testosterone undecanoate capsules (Jatenzo): the first 50 patients. J Sex Med. 2022;19:S128.
- Swerdloff RS, Wang C, White WB, et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J Clin Endocrinol Metab. 2020;105:2515–2531.
- DelConte A, Papangkorn K, Kim K, et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022;10:669–676.
- Shirai M, Mizushima K, Tsuru T, et al. Novel testosterone gel improves aging males’ symptoms in patients with late-onset hypogonadism: active control equivalence, randomized, double-blind, crossover pilot study. J Sex Med. 2022;19:S177.
- Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study. J Sex Med. 2019;16:1741–1748.
- Moon DG, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7:2253–2260.
- Alwani M, Al-Zoubi RM, Al-Qudimat A, et al. The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: an observational cohort study. Annals of Medicine & Surgery. 2021;69 [[cited 2023 Mar 14]]. InternetAvailable from: https://journals.lww.com/10.1016/j.amsu.2021.102748
- Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging. 2007;2:577–590.
- Strange RC, König CS, Ahmed A, et al. Testosterone therapy: increase in hematocrit is associated with decreased mortality. Androgens: Clin Res Ther. 2021;2:150–159.
- Masterson TA, Turner D, Vo D, et al. The effect of longer-acting vs shorter-acting testosterone therapy on follicle stimulating hormone and luteinizing hormone. Sexual Med Rev. 2021;9:143–148.